CSPC Wins U.S. FDA Nod for Once-Monthly Semaglutide Trial
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
The latest announcement is out from CSPC Pharmaceutical Group ( (HK:1093) ).
CSPC Pharmaceutical Group announced that its independently developed Semaglutide Long-acting Injection (SYH9017), a once-monthly GLP-1 receptor agonist, has received approval from the U.S. Food and Drug Administration to commence clinical trials. The product uses a long-acting delivery platform to form a subcutaneous gel depot, aiming to extend dosing from once weekly to once monthly and thereby improve patient adherence while maintaining comparable weight loss efficacy and a favorable safety profile.
The initial U.S. clinical trial will target weight management in overweight or obese adults in conjunction with diet and exercise, with additional potential indications in type 2 diabetes and cardiovascular risk reduction. As the company’s first long-acting once-monthly GLP-1 preparation, SYH9017’s progress in the U.S. market strengthens CSPC’s innovation credentials, supports future pipeline development, and could enhance its competitive positioning in the rapidly growing metabolic and obesity treatment segment.
The most recent analyst rating on (HK:1093) stock is a Buy
with a HK$13.05 price target.
To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock,
see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong–incorporated pharmaceutical company focused on developing innovative drugs, with a particular emphasis on advanced delivery technologies and treatments for metabolic and chronic diseases. The group operates through multiple subsidiaries and is listed on the Hong Kong Stock Exchange under stock code 1093, reflecting its role as a major regional player in the healthcare sector.
YTD Price Performance: -14.12%
Average Trading Volume: 95,643,013
Technical Sentiment Signal: Hold
Current Market Cap: HK$83.28B
For an in-depth examination of 1093 stock, go to TipRanks’ Overview page.
